Completion surgery

Ask about this lesson

In one sentence

Completion surgery is a further operation at the same site, done because pathology from the first operation shows that local treatment is not finished.

The intuition

The first operation is also a measurement. Only after the pathologist examines the removed tissue does the team know whether cancer touched the cut edge, or whether the first nodes removed still held cancer. Completion surgery is going back to finish the job the measurement says is unfinished. The analogy breaks because "finishing" can sometimes be done by radiation instead of a knife, and trials exist to test exactly that.

How it works

There are three common kinds in breast cancer:

Kind	Trigger in the pathology report	What the second operation does
Re-excision	A margin that fails the applicable margin standard after lumpectomy, such as ink on invasive tumor	Removes more tissue around the cavity
Completion mastectomy	Margin involvement that further excision is unlikely to clear; a margin finding alone does not choose this operation	Removes the rest of the breast
Completion axillary lymph node dissection (ALND)	Cancer in the sentinel or marked nodes	Removes the remaining level I–II armpit nodes

Each is a local decision. It does not treat cancer elsewhere in the body; systemic therapy does that job.

When trials replaced the second operation

The node question has been tested most. Three trials show how the answer depends on the setting:

Trial	Setting	Comparison	Result
ACOSOG Z0011	Surgery first; clinical T1–T2 cancer, no palpable nodes, one or two positive sentinel nodes, lumpectomy plus whole-breast radiation; 891 randomized	Completion ALND versus sentinel-node surgery alone	10-year overall survival 86.3% without dissection versus 83.6% with it; non-inferior (hazard ratio 0.85)
EORTC AMAROS	Surgery first; T1–T2 cancer, no palpable nodes, positive sentinel node; 1,425 in the analysis	Completion ALND versus axillary radiation	5-year axillary recurrence 0.43% after dissection versus 1.19% after radiation; lymphedema significantly more common after dissection
Alliance A011202	After neoadjuvant chemotherapy; clinical T1–3 N1 cancer with a sentinel node still positive; 2,012 enrolled	Completion ALND plus nodal radiation versus axillary plus nodal radiation	Not yet reported; registry primary completion estimated 2031

In AMAROS, 33% of patients who had the dissection had additional positive nodes, yet armpit recurrence stayed low in both groups. Finding more cancer by removing more nodes is not the same as preventing more recurrences.

Why it matters in cancer

A second operation adds recovery time and, for axillary dissection, a higher risk of lymphedema (arm swelling).
Its trigger is a pathology finding, so the margin or node result needs to be read precisely before the decision.
After neoadjuvant therapy, residual node cancer means some cancer survived treatment. That is a different situation from a positive sentinel node found at surgery-first, so surgery-first trials do not transfer directly.

Common confusions

Completion versus staging surgery. Sentinel-node biopsy samples nodes to stage the cancer. Completion dissection treats the armpit after the sample is positive.
Z0011 after neoadjuvant therapy. Z0011 enrolled surgery-first patients treated with lumpectomy. It does not answer the post-neoadjuvant question; A011202 is testing that.
Re-excision versus recurrence. Re-excision follows a margin finding at the first operation. It is not a sign that cancer came back.
Radiation as a substitute. AMAROS replaced dissection with axillary radiation, not with nothing. Z0011 omitted dissection in people who still received whole-breast radiation.

Worked example

Fictional report. After neoadjuvant chemotherapy, one of three sentinel nodes contains a 4 mm deposit. A friend says, "Z0011 showed you don't need more node surgery." What is missing?

Answer: Z0011 enrolled people who had surgery first. This report follows neoadjuvant chemotherapy, where residual node disease is the setting A011202 is testing and has not yet reported. The friend's trial is from a different population.

Explain it back

Fill in: "Completion surgery is triggered by ___ from the first operation, and whether radiation can replace it depends on ___."

One answer: a margin or node finding in the pathology; the setting the trial tested, including whether surgery came first or after neoadjuvant therapy.

Takeaway

Completion surgery finishes local treatment that the first operation's pathology showed was incomplete; trials have replaced completion node surgery in some surgery-first settings, but the post-neoadjuvant question is still being tested.

Sources and scope

Source check: November 7, 2026. Concept and trial designs only; no individual surgical recommendation. Expert and learner review pending.

Giuliano et al., 2017: ACOSOG Z0011 10-year results, JAMA — complete abstract checked.
Donker et al., 2014: EORTC AMAROS, Lancet Oncology — complete abstract checked for population, recurrence, additional positive nodes and lymphedema.
ClinicalTrials.gov NCT01901094: Alliance A011202 — eligibility, arms (level I–II dissection), enrollment and status checked November 7, 2026.
Moran et al., 2014: margin consensus — scope of "no ink on tumor"; detailed on the margins page.